U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major ...

Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 10.90%, which has investors questioning if this is right time to buy.

Volatility and Risk Finch Therapeutics Group has a beta of 1.21, indicating that its share price is 21% more volatile than ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Onvida Health is bringing a new era of precision and early detection to lung cancer care in Yuma. The hospital has introduced ...

WARREN, NJ, USA I March 28, 2025 I PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.